We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMEA Outlines Requirements for GERD Drug Studies
EMEA Outlines Requirements for GERD Drug Studies
January 14, 2010
The European Medicines Agency (EMEA) recommends that sponsors testing gastroesophageal reflux disease (GERD) treatments for reflux esophagitis in Phase
III trials use a primary endpoint of complete healing of mucosal breaks. Includes the full text of EMEA Draft Guidance on GERD Drug Development.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor